Allergy Asthma Respir Dis.  2019 Apr;7(2):109-112. 10.4168/aard.2019.7.2.109.

A case of rapid desensitization for rituximab-induced delayed hypersensitivity reaction

Affiliations
  • 1Wonkwang University College of Pharmacy, Iksan, Korea.
  • 2Drug Safety Monitoring Center Seoul National University Hospital, Seoul, Korea. helenmed@snu.ac.kr
  • 3Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • 4Seoul National University College of Pharmacy, Seoul, Korea.
  • 5Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Rituximab is a monoclonal antibody used for the treatment of B-cell malignancies, including diffuse large B-cell lymphoma. Infusion-related hypersensitivity reactions to rituximab is well known, and delayed hypersensitivity reactions to rituximab are also reported. Desensitization is commonly used to prevent immediate hypersensitivity reactions, but recently there have been cases of successful desensitization therapy for delayed hypersensitivity reactions. A 66-year-old patient who underwent rituximab treatment for diffuse large B-cell lymphoma showed repeated rituximab-induced delayed hypersensitivity reactions with whole body rashes. Intravenous rapid desensitization was performed by using a 1-bottle, 11-step protocol for 6 cycles and thereafter hypersensitivity reaction did not recur. We herein reported a case of delayed hypersensitivity reaction caused by rituximab, which was successfully desensitized using our 11-step protocol.

Keyword

Rituximab; Delayed hypersensitivity; Immunologic desensitization

MeSH Terms

Aged
B-Lymphocytes
Desensitization, Immunologic
Exanthema
Humans
Hypersensitivity
Hypersensitivity, Delayed*
Hypersensitivity, Immediate
Lymphoma, B-Cell
Rituximab
Rituximab
Full Text Links
  • AARD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error